Compare NRXP & CXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRXP | CXH |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 66.4M |
| IPO Year | N/A | N/A |
| Metric | NRXP | CXH |
|---|---|---|
| Price | $1.77 | $8.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $31.50 | N/A |
| AVG Volume (30 Days) | ★ 489.9K | 21.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $847.91 | N/A |
| P/E Ratio | ★ N/A | $35.94 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $7.34 |
| 52 Week High | $3.84 | $8.39 |
| Indicator | NRXP | CXH |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 58.35 |
| Support Level | $1.65 | $7.94 |
| Resistance Level | $1.99 | N/A |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 30.16 | 53.23 |
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.